ARCA biopharma Announces Second Quarter 2018 Financial Results and Provides Corporate Update
09 août 2018 16h15 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., Aug. 09, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
ARCA Biopharma Announces Positive Outcome of End-of-Phase 2 Meeting With FDA on Gencaro Development for Atrial Fibrillation
31 juil. 2018 08h30 HE
|
ARCA biopharma, Inc.
Single Phase 3 trial may be sufficient for approval of atrial fibrillation indicationPhase 3 clinical trial Special Protocol Assessment submission anticipated 3Q2018Gencaro is in development as...
GENETIC-AF Phase 2B Clinical Trial Results Presented in Late Breaking Presentation at European Society of Cardiology Heart Failure 2018 World Congress
29 mai 2018 08h30 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., May 29, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
ARCA biopharma Announces Phase 2B GENETIC-AF Clinical Trial Results Selected for Late Breaking Oral Presentation at European Society of Cardiology Heart Failure 2018 World Congress
10 mai 2018 08h30 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., May 10, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
ARCA Biopharma announces first quarter 2018 financial results AND Provides Corporate Update
08 mai 2018 16h15 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., May 08, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
ARCA biopharma Reports Topline Phase 2B Results for GENETIC-AF Clinical Trial
26 févr. 2018 08h00 HE
|
ARCA biopharma, Inc.
-------------------------------------------------------------------------------------------------- Gencaro Demonstrates Comparable Efficacy to Active Control and Trend for Potential Gencaro...
ARCA biopharma Announces Completion of GENETIC-AF Phase 2B Clinical Trial
08 janv. 2018 08h30 HE
|
ARCA biopharma, Inc.
-------------------------------------------------------------------------------------------------- GENETIC-AF Evaluating Gencaro as Potentially First Genetically-Targeted Treatment for Atrial...
ARCA biopharma Announces Third Quarter 2017 Financial Results and Provides Business Update
09 nov. 2017 16h05 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., Nov. 09, 2017 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
ARCA biopharma Announces Completion of Enrollment for GENETIC-AF Phase 2B Clinical Trial
16 août 2017 08h30 HE
|
ARCA Biopharma, Inc.
GENETIC-AF Evaluating Gencaro as Potentially First Genetically-Targeted Treatment for Atrial Fibrillation ARCA Estimates Reporting Top-line Phase 2B Data in the First Quarter of 2018 WESTMINSTER,...
ARCA biopharma Announces GENETIC-AF Data and Safety Monitoring Board Recommendation to Complete Phase 2B GENETIC-AF Clinical Trial Based on Efficacy and Safety Data in Phase 2B Interim Analysis
09 août 2017 16h30 HE
|
ARCA Biopharma, Inc.
ARCA Estimates Reporting Top-line Phase 2B Data in the First Quarter of 2018Gencaro Development Program Has Been Granted Fast Track Designation by U.S. FDA WESTMINSTER, Colo., Aug. 09, 2017 (GLOBE...